We're not Building Another Therapy.
We're Building the Supply Chain.
IBOGAINE DOESN'T SCALE WITHOUT INFRASTRUCTURE. BEFORE THERE IS MEDICINE, THERE HAS TO BE SUPPLY. WE'RE BUILDING IT.
VISION
We’re Here to Solve PTSD & End the Opioid Crisis
Pharmagaine’s mission is to build a new ‘plant-to-pill’ model for next frontier pharmaceutical compounds sourced from the iboga tabernathe tree that could solve PTSD and end the opioid crisis - one that blends disciplined science with sustainable local market sourcing, restores dignity through healing, and uplifts local communities where the plants are traditionally grown through meaningful and impactful parnerships.
The Future of Ibogaine Doesn’t Start in a Lab.
It Starts at the Source.
OUR ADVANTAGE
Scaled access to the World's Largest Source of Ibogaine.
WORLD'S LARGEST IBOGA FARM LOCATED IN THE DEMOCRATIC REPUBLIC OF THE CONGO
125
Acres of Farming Land Owned & Operated by Pharmagaine
5,000+
Mature Iboga Plants Ready for Full Plant Extraction
Pharmagaine has purchased 125 Acres of prime farming land in the Democratic Republic of the Congo where the plant grows in its natural biosphere with unmatched genetics.
Our access to responsibly cultivated iboga in the Congo will reset the global ibogaine market by creating a more reliable and traceable supply chain currently dominated by illegal, pirated, and smuggled iboga from Gabon where the plant is strictly protected.
With government-issued permits for cultivation and the only export license for Ibogaine Export issued by the Ministry of Agriculture (DRC), Pharmagaine's operation ends the industry's prior reliance on unsustainable and unlicensed harvesting, creates a reliable and legal supply chain for the global research community, and supports sustainable use and benefit-sharing with local communities where the plant has grown naturally for thousands of years.
CENTER OF EXCELLENCE BEING BUILT IN 2027 IN KHINSHASA FREE-TRADE ZONE
2 Acre
Secure Production Facility
ISO 9001
Quality Management Systems
Our Center of Excellence in Khinshasa will be built to the highest international standards so that we can ensure that our research partners, pharmaceutical and therapeutic clients have the most reliable and purest source of Ibogaine and other Iboga-derived Alkaloids possible.
RESEARCH PARTNERSHIPS FOCUSED ON IP & DRUG DEVELOPMENT PARTNERSHIPS
30
Global Research Partners Identified
$37.7B
Global Drug Addiction Treatment Market (2027)
Pharmagaine is in the early stages of securing a range of Research Partnerships focused on IP and Drug Developments that treat PTSD and opioid addiction. Significant promise also exists to treat other forms of trauma, stimulant and other addictions, TBI, anxiety and depression.
WHY PHARMAGAINE
Creating a Vertically Integrated Sustainable Supply Chain for the Global Pharmaceutical Industry
Our belief is that the future of medicine must be both rigorous and responsible. Our combined expertise in regulatory affairs, sustainable farming practices, and startup discipline with a profound respect for local knowledge in the DRC and environmental stewardship sets us apart.
We operate at the intersection of corporate discipline, entrepreneurial agility, and boots-on-the-ground collaborations.
To date, over a dozen US States are actively working on legislative initiatives related to ibogaine, primarily focusing on funding research, clinical trials, and pursuing FDA approval for treating opioid use disorder and PTSD.
The question "where will they get the ibogaine from?" has not been answered yet by the industry... until now.
PHARMAGAINE OPPORTUNITY
US Opioid Crisis
$1.3T
Annual Cost of Opioid Crisis to US Economy
332M
Number of People Globally Suffering from Depression
$37.7B
Size of the Global Drug Addiction Treatment Market
80%
Success Rate Reducing or Eliminating Withdrawl Symptoms from Opioids
COLLABORATION
Industry Groups we Support
